MedPath

Patiromer

Generic Name
Patiromer
Brand Names
Veltassa
Drug Type
Small Molecule
CAS Number
1260643-52-4
Unique Ingredient Identifier
1FQ2RY5YHH

Overview

Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads.

Background

Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads.

Indication

Patiromer is indicated for the treatment of hyperkalemia.

Associated Conditions

  • Hyperkalemia

Clinical Trials

Phase 3
Not yet recruiting
Posted: 2025/03/05
Sponsor:
Mario Negri Institut...
Phase 3
Terminated
Posted: 2023/03/27
Sponsor:
Mario Negri Institut...
Phase 3
Recruiting
Posted: 2021/11/29
Sponsor:
Vifor Fresenius Medi...

FDA Approved Products

VELTASSA
Manufacturer:Vifor Pharma, Inc.
Route:ORAL
Strength:16.8 g in 1 1
Approved: 2023/10/10
NDC:53436-168
VELTASSA
Manufacturer:Vifor Pharma, Inc.
Route:ORAL
Strength:8.4 g in 1 1
Approved: 2023/10/10
NDC:53436-084
VELTASSA
Manufacturer:Vifor Pharma, Inc.
Route:ORAL
Strength:25.2 g in 1 1
Approved: 2023/10/10
NDC:53436-252

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath